24/7 Patient Assistance: 760-405-8205

Mark A. Socinski, MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Lung Cancer

specialties & services

  • Bio & Insurance Information

    Dr. Mark Socinski graduated medical school from University of Vermont College of Medicine and completed his residency program at Beth Israel Deaconess Medical Center. A fellowship in medical oncology followed at the Dana-Farber Cancer Institute. Dr. Socinski is specialized in oncology and board certified in internal medicine and medical oncology. He has been in practice for more than 20 years and is a member of several medical organizations, including the American College of Chest Physicians and also the American Society of Clinical Oncology.

  • Education & Training


    University of Vermont College of Medicine Graduated in 1984

    Medical School


    Beth Israel Deaconess Medical Center Completed in 1986



    Dana-Farber Cancer Institute Completed in 1989


  • Board Certifications

    American Board of Internal Medicine

    American Board of Internal Medicine - Oncology

  • Hospital & Practice

    Magee Womens Hospital of UPMC Pittsburgh

    Languages: English/Spanish

    (412) 641-1000

    300 Halket St

    Pittsburgh, Pennsylvania 15213

    Read More

    UPMC Presbyterian Shadyside

    Languages: English/Spanish

    (412) 647–2345

    200 Lothrop Street

    Pittsburgh, Pennsylvania 15213-2536

    Read More
  • Publications & Memberships

    Dr. Mark A. Socinski has contributed to 3 publications.

    Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitu.

    Paz-Ares, L.,Socinski, M. A.,Shahidi, J.,Hozak, R. R.,Soldatenkova, V.,Kurek, R.,Varella-Garcia, M.,Thatcher, N.,Hirsch, F. R.; Ann. Oncol.. 2016 May 22

    See more >>

    Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes

    Villaruz, L. C.,Socinski, M. A.; Eur. J. Cancer. 2016 Feb 15

    See more >>

    Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

    Shaw, A. T.,Gandhi, L.,Gadgeel, S.,Riely, G. J.,Cetnar, J.,West, H.,Camidge, D. R.,Socinski, M. A.,Chiappori, A.,Mekhail, T.,Chao, B. H.,Borghaei, H.,Gold, K. A.,Zeait...; Lancet Oncol.. 2015 Dec 29.

    See more >>


    American College of Chest Physicians

    American College of Physicians

    American Society of Clinical Oncology

    International Association for the Study of Lung Cancer